Aurora A kinase (AURKA) in normal and pathological cell division

Scientific literature lacks a comprehensive synthesis regarding the dual roles of this protein in both healthy and diseased cellular states. Prior research has shown that precise temporal regulation is required for proper spindle assembly. That uncertainty drove interest in how dysregulation contributes to genomic instability. It was already known that overexpression occurs frequently within various solid malignancies. This gap motivated a deeper look at the structural basis for kinase activation. No prior work had resolved how non-mitotic functions influence therapeutic outcomes. Investigators have long studied its involvement in centrosome maturation and cytokinesis. Recent evidence suggests that interphase activities might complicate current clinical inhibition strategies.

The aim of this review is to clarify the mitotic and non-mitotic functions of this kinase. Researchers seek to resolve how structural regulation influences its activity in various cellular contexts. This work addresses the specific problem of how protein overexpression leads to malignant transformation. The authors intend to bridge the gap between basic cell biology and clinical therapeutic development. They examine the motivation for targeting this enzyme in patients with solid tumors. The study explores why current inhibitors might face challenges due to unexpected interphase roles. Investigators provide a comprehensive assessment of the current state of clinical trials. This analysis serves to guide future research into the complex signaling pathways involved.

This review approach synthesizes existing literature regarding kinase regulation and cellular function. The authors examine structural biology data to explain activation mechanisms. They evaluate clinical trial reports to assess current therapeutic progress. The study integrates findings from both mitotic and interphase research. Investigators contrast healthy division processes with pathological states found in tumors. The analysis focuses on the relationship between protein overexpression and genomic instability. The team reviews evidence linking non-mitotic activities to broader cellular physiology. This systematic summary provides a framework for interpreting current drug development challenges.

Key findings from the literature indicate that this kinase is frequently overexpressed in many solid tumor types. The authors report that this amplification is strongly associated with aneuploidy and defective mitotic spindles. Evidence shows that supernumerary centrosomes often arise from dysregulated kinase activity. The review highlights that these properties contribute to resistance against apoptosis in malignant cells. Data suggest that non-mitotic functions, such as neurite elongation, are emerging as significant areas of study. The researchers find that these additional roles may influence the clinical performance of current inhibitors. The synthesis confirms that multiple agents are currently undergoing early-phase testing. The literature indicates that spatial control of the protein is vital for successful cytokinesis.

The authors synthesize evidence indicating that this kinase governs critical mitotic events through precise spatial control. They highlight that genetic amplification correlates strongly with the presence of supernumerary centrosomes in tumors. The review suggests that non-mitotic roles during neurite elongation provide new context for understanding cellular physiology. Researchers propose that these diverse functions may explain observed variations in clinical inhibitor performance. The synthesis implies that targeting this protein requires accounting for its complex structural regulation. Authors emphasize that current clinical trials must consider these broader biological activities. The analysis confirms that inhibiting this target remains a high-priority strategy for oncology. Finally, the work underscores the need for integrated models of mitotic and interphase signaling.